Cassava Sciences Has Good News from Alzheimer’s Disease Trial. See Also: Theravance Biopharma

Cassava Sciences
From  NEWSWIRE we learned that Cassava Sciences (SAVA), a clinical-stage biotechnology company focusing on Alzheimer’s disease, announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community, has published results from the Company’s Phase 2a study; its drug PTI-125

This content is for paid subscribers.
Please click here to subscribe or here to log in.